Clinical Trials Logo

Small Cell Carcinoma clinical trials

View clinical trials related to Small Cell Carcinoma.

Filter by:

NCT ID: NCT00469222 Completed - Lung Neoplasm Clinical Trials

Hypofractionated Radiotherapy for Small Cell Lung Cancer

Start date: March 2007
Phase: Phase 1
Study type: Interventional

Current treatments for limited stage small cell lung cancer have poor cure rates. The addition of chest radiation to chemotherapy improves cure rates, but these cancers still come back in the chest 30-50% of the time. Two factors which can improve control and cure rates for this cancer are increasing the chest radiation dose and minimizing the overall time it takes to complete radiation treatments. One method to achieve both of these goals is to give more radiation each day. This study is meant to study how tolerable and effective it would be to increase the intensity of chest radiation for small cell lung cancer patients by increasing the daily radiation dose. We aim to find the highest dose of chest radiotherapy that can be safely given with chemotherapy using this strategy. Patients in this trial will be monitored before, during and after their radiation and chemotherapy treatments for treatment side-effects, how effective treatments are at controlling their cancer and quality of life changes. Results from this trial will help to define more effective radiotherapy doses which are tolerable for this type of lung cancer and the quality of life changes patients experience when they undergo these treatments.

NCT ID: NCT00469066 Completed - Lung Neoplasm Clinical Trials

Cone Beam CT Scanning in Lung and Bladder Cancer.

Start date: May 2007
Phase: N/A
Study type: Observational

To study changes in tumor and normal organ size and/or position which occur during a course of radiation treatments.

NCT ID: NCT00466232 Completed - Lung Cancer Clinical Trials

Phase I Study of Weekly Topotecan in Combination With Sorafenib in Treatment of Relapsed Small Cell Lung Cancer

Start date: April 2007
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to determine the maximum tolerated dose of sorafenib up to the full active dose when combined with standard weekly dosing of topotecan in patients with recurrent small cell lung cancer and to characterize the toxicities associated with the combination of topotecan and sorafenib in this patient population